Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers
Article excerpt
Highlighted: the sentence this signal was extracted from
Waters WAT recently received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, enabling their commercialization in the United States. The ready-to-use flow cytometry tests are designed to aid in identifying and diagnosing B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). The solution offers standardized diagnostic workflows, delivering 96.3% sensitivity and 98.2% specificity in identifying CLL. Per management, the FDA clearance marks an important milestone in expanding access to reliable, high-quality flow cytometry diagnostics for blood cancers. The company aims to simplify diagnostic procedures and minimize variability across laboratories while establishing a foundation for introducing standardized tests for additional blood cancers in the future. The clearance is significant given the prevalence of blood cancers in the United States. An estimated 79,320 people are expected to be diagnosed with NHL in 2026, including 22,760 cases of CLL. The BD OneFlow LST and BD OneFlow B-CLPD T1 Tests are currently open for preorders and are expected to launch commercially in the United States in spring 2027 through online channels and local sales representatives. Following the announcement, shares of WAT rose 2.9% at yesterday's close. Year to date, the stock jumped 25.2%, outperforming the industry's 4.7% growth and the S&P...
Keep reading with a free account
The rest of this article, and every signal for Waters, is in your free account.
